Changes in Hong Kong stocks | Boan Biotech (06955) rose more than 4%. Recently, the BA1203 clinical trial application was accepted by CDE and will become an important layout for the company's next generation IO treatment

The Zhitong Finance App learned that Boan Biotech (06955) rose by more than 4%. As of press release, it had risen 2.76% to HK$4.84, with a turnover of HK$12.193,200.

According to the news, recently, Boan Biotech announced that the new drug clinical trial application (IND) for BA1203, the PD-1/IL-2 antibody cytokine precursor drug under development, has been accepted by the Drug Evaluation Center of the China National Drug Administration. BA1203 is a next-generation tumor immunization candidate independently developed by the company. It is intended to be developed for the treatment of various solid tumors. According to the company's knowledge, the drug under development will be the first shielded PD-1/IL-2 antibody cytokine to enter clinical trials that preserve subunit binding activity in China.

According to the announcement, BA1203 is an important layout for the company in next-generation IO treatment. With high-affinity bivalent PD-1 targeting, IL-2 shielding prodrug, and symmetric molecular structure design, the drug under development is expected to build core advantages in terms of efficacy and safety. The company will accelerate the clinical development of BA1203, further explore its single drug and combination treatment development paths, and continue to verify its potential for differentiated treatment.